RSV Vaccines for the World 2013 Conference Presentation Highlights Data from ADMA Biologics, Inc.’ Human and Animal Study Experience
10/29/2013 6:54:03 AM
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases announced today that data from its previous Phase II trial, compassionate use experience and testing in the cotton rat RSV animal model was presented at the 2013 RSV Vaccines for the World Conference (RSVVW).
Help employers find you! Check out all the jobs and post your resume.
comments powered by